Complex Cisplatin-Double Strand Break (DSB) Lesions Directly Impair Cellular Non-Homologous End-Joining (NHEJ) Independent of Downstream Damage Response (DDR) Pathways
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The treatment for advanced stage non-small cell lung cancer (NSCLC) often includes platinum-based chemotherapy and IR. Cisplatin and IR combination therapy display schedule and dose-dependent synergy, the mechanism of which is not completely understood. In a series of in vitro and cell culture assays in a NSCLC model, we investigated both the downstream and direct treatment and damage effects of cisplatin on NHEJ catalyzed repair of a DNA DSB. The results demonstrate that extracts prepared from cisplatin-treated cells are fully capable of NHEJ catalyzed repair of a DSB using a non-cisplatin-damaged DNA substrate in vitro . Similarly, using two different host cell reactivation assays, treatment of cells prior to transfection of a linear, undamaged reporter plasmid revealed no reduction in NHEJ compared with untreated cells. In contrast, transfection of a linear GFP-reporter plasmid containing site-specific, cisplatin lesions 6-bp from the termini revealed a significant impairment in DSB repair of the cisplatin-damaged DNA substrates in the absence of cellular treatment with cisplatin. Together, these data demonstrate that impaired NHEJ in combined cisplatin-IR treated cells is likely the result of a direct effect of cisplatin-DNA lesions near a DSB and that the indirect cellular effects of cisplatin treatment are not significant contributors to the synergistic cytotoxicity observed with combination cisplatin-IR treatment. Background: The biochemical mechanism of cisplatin-IR synergy is incompletely understood. Results: NHEJ of non-cisplatin damaged DNA substrates is unaltered by cellular cisplatin treatment while repair of cisplatin-DSB lesions is inhibited independent of cellular cisplatin treatment. Conclusion: Cisplatin-DSB compound lesions directly inhibit NHEJ while cisplatin-activated pathways do not impact NHEJ. Significance: The mechanism of cisplatin-IR synergy involves direct inhibition of NHEJ by compound cisplatin-DSB lesions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
DNA end-joining catalyzed by human cell-free extracts
Baumann, P., & West, S. C. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.24.14066 · Cited by 295
Differential activation of DNA-PK based on DNA strand orientation and sequence bias
Pawelczak, K. S. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki157 · Cited by 42
Cited by
Opportunities and challenges of radiotherapy for treating cancer
Schaue, D., & McBride, W. H. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.120 · Cited by 784
DNA damage-how and why we age?
Yousefzadeh, M., Henpita, C., Vyas, R., Soto-Palma, C., Robbins, P., & Niedernhofer, L. (2021) · eLife · doi:10.7554/elife.62852 · Cited by 399
DNA repair targeted therapy: The past or future of cancer treatment?
Gavande, N. S., VanderVere-Carozza, P. S., Hinshaw, H. D., Jalal, S. I., Sears, C. R., Pawelczak, K. S., & Turchi, J. J. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.02.003 · Cited by 387
Self-citationMolecular mechanisms of fatty acid synthase (FASN)-mediated resistance to anti-cancer treatments
Wu, X., Qin, L., Fako, V., & Zhang, J.-T. (2014) · Advances in Biological Regulation · doi:10.1016/j.jbior.2013.09.004 · Cited by 82
Metadata
- Authors
- Sears, C. R., & Turchi, J. J.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2012-07
- Volume
- 287
- Issue
- 29
- Pages
- 24263-24272
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1968509601
- Cited by
- 65
- References
- 3
- FWCI
- 1.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Complex Cisplatin-Double Strand Break (DSB) Lesions Directly Impair Cellular Non-Homologous End-Joining (NHEJ) Independent of Downstream Damage Response (DDR) Pathways. https://app.cochat.ai/papers/10.1074/jbc.m112.344911
- The paper
- Sears, C. R., & Turchi, J. J. (2012). Complex Cisplatin-Double Strand Break (DSB) Lesions Directly Impair Cellular Non-Homologous End-Joining (NHEJ) Independent of Downstream Damage Response (DDR) Pathways. Journal of Biological Chemistry. https://doi.org/10.1074/jbc.m112.344911
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.